Skip to Main Content

Author Details

Euan A Stronach
Imperial College London
1999
38
24
PMIDPaper TitleJournal TitlePublished Year
36706533Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.Drug Resist Updat2023
37220750Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.Cell Rep Med2023
32437684CELLector: Genomics-Guided Selection of Cancer In Vitro Models.Cell Syst2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
30563934Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res2019
30261145Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.Cancer Biol Ther2019
31097696Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.Nat Commun2019
30971826Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.Nature2019
30722791Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.Genome Biol2019
29724815Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.Mol Cancer Res2018
30103702Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.BMC Genomics2018
28710496Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep2017
27353039MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.Endocr Relat Cancer2016
27206315Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.Cell Death Differ2016
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26429956Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.J Nucl Med2015
26267317The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.Oncotarget2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26579492Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy.Front Oncol2015
26497682A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Oncotarget2015
26493647Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.Nat Rev Cancer2015
23948749Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.Mod Pathol2014
24860781Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.Front Oncol2014
24727386Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.Biochim Biophys Acta2014
23128397Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.Oncogene2013
23727325Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.Cytokine2013
22484552Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.Mol Imaging Biol2012
21459799Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Clin Cancer Res2011
22131882DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.Neoplasia2011
21941283Rethinking ovarian cancer: recommendations for improving outcomes.Nat Rev Cancer2011
21571862HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.Cancer Res2011
19363526Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.Oncogene2009
18312212Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods.Stat Appl Genet Mol Biol2008
12819783OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.Nat Genet2003
14695176Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.Cancer Res2003
11585719BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.Cancer Res2001
10442687Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies.J Peripher Nerv Syst1999
  • 1 - 38 of 38

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 1
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 7
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 5
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 0
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 2
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 3
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 13
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 8
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 3
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 19
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 5
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 30
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 28
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 1
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 3
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 14
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 47
John M S Bartlett
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 10
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 2
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 8
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5

Collaborators

Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 7
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 7
Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 5
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 5
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 4
Kosuke Yusa
Wellcome Sanger Institute
Co-authored papers 4
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 4
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 4
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 4
Ernst Lengyel
University of Chicago
Co-authored papers 4
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 4
Huei San Leong
Peter MacCallum Cancer Centre
Co-authored papers 4
Anna DeFazio
Westmead Hospital
Co-authored papers 4
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 4
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 4
Ronny Drapkin
University of Pennsylvania School of Medicine
Co-authored papers 4
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 4
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 4
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 3
Liz-Anne Lewsley
CRUK Clinical Trials Unit, University of Glasgow
Co-authored papers 3
Andrew Berchuck
Duke School of Medicine
Co-authored papers 3
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 3
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Co-authored papers 3
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 3
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 3
David G Huntsman
University of British Columbia
Co-authored papers 3
Valerie Rhenius
University of Cambridge
Co-authored papers 2
George Au-Yeung
The University of Melbourne
Co-authored papers 2
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 2
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 2
Release 1.2